There are an increasing number of markers that are used to predict the occurrence of type 1 diabetes (T1D), and to study the progression of pathologic changes prior to diagnosis. This review discusses some of those markers, particularly markers for which data are available that pertain to the progression to T1D.
INTRODUCTION
A number of markers have been identified that are indicative of the risk for type 1 diabetes (T1D), including genetic, demographic, immunologic, and metabolic characteristics. Some of these risk markers change during the progression to T1D and have been used to characterize its development. In fact, the degree of risk for T1D and the changes in these markers can be intertwined; as the markers change, the risk changes. Thus, in discussing markers that have been identified and developed for following the progression to T1D, risk will often be considered. The particular markers included in this review were selected because they have been studied during the progression to T1D. Although the decline of the b-cell can continue for a number of years after diagnosis, this review will be limited to the use of markers prior to diagnosis and in the peridiagnostic period. Following the review of the markers, a system for staging the progression to T1D will be proposed.
AUTOANTIBODY MARKERS
Autoantibodies have long been known to be risk factors for T1D [1] [2] [3] [4] [5] [6] [7] . However, more recently there has been interest in relating their characteristics to T1D progression. Although autoantibodies have potential in this regard, it will be evident below that much is still to be learned. young children is indicative of the inevitability of T1D. This will ultimately be determined as children with multiple autoantibodies continue to be followed.
Relatives of T1D patients who are identified as having multiple autoantibodies are also at high risk for T1D, but their risk does not appear to be as high as children followed from birth [7] . Explanatory factors for these differences have not been identified, but could include age, types of autoantibodies, and such characteristics as affinity and titers. Whatever the basis, it is clear that in both children and adults the development of multiple autoantibodies is a significant milestone in the progression to T1D.
Autoantibody type
There are known differences in the degree of risk according to types of autoantibodies. For example, in an autoantibody positive cohort, individuals with IA-2A autoantibodies were at greater risk than those with GADA autoantibodies [7] . This suggests that IA-2A autoantibodies appear closer to the diagnosis of T1D. A study [9] has shown that among a population of autoantibody positive relatives of T1D patients followed for an average of approximately 3 years, the proportion of those with GADA positivity was high at baseline with a small decrease at diagnosis (81-77%, respectively), whereas the proportion positive for IA-2A increased appreciably from baseline to diagnosis (58-81%; P < 0.001).
Recent data from birth cohorts at risk for T1D suggest that IAA autoantibodies are more commonly the initial autoantibody to appear, with a peak between the first and second year. When GADA appears first, it tends to occur later, with a peak at 3-5 years [10] . More longitudinal data are needed to more precisely understand how changes in types of autoantibodies relate to the progression to T1D.
Autoantibody titer
Even when autoantibodies are positive, titers appear to contribute to the prediction of T1D [5] [6] [7] 10, 11] . In the study [9] that examined changes in GADA and IA-2A positivity, among those positive at baseline, IA-2A titers were increased at diagnosis; conversely, GADA titers decreased ( Fig. 1 ). Similar to other autoantibody characteristics, there is insufficient natural history information regarding changes in titers to know whether they can be useful markers for assessing progression.
Autoantibody affinity
Studies have shown that the risk for T1D could be related to autoantibody affinity [12, 13] . Electrochemiluminescence (ECL) measurements of autoantibodies, which are indicative of autoantibody
KEY POINTS
Markers have recently been identified which contribute to the prediction accuracy for T1D, an understanding of its natural history, and the design of prevention trials for the disorder.
Markers for T1D can be combined into scores to enhance their utility for prediction.
Markers can be used alone or in combination to serve as prediagnostic endpoints for T1D prevention trials.
Markers have provided information which should lead to a more detailed staging of the development of T1D.
Markers have provided information which could lead to an earlier diagnosis of T1D. affinity, have been shown to improve the prediction accuracy for T1D [14,15,16 & ]. They also appear to predict progression from single to multiple autoantibodies [16 & ]. However, their value as markers for progression in longitudinal studies is not known. More needs to be learned about how ECL positivity relates to the natural history of T1D. For example, it would be helpful to know whether the development of ECL positivity defines a stage of progression.
GLUCOSE MARKERS
The level of glycemia has been used to study the progression to T1D. Importantly, glycemic thresholds have been used as the gold standard for T1D. Thus, the degree of progression can be assessed by relating glucose levels to diagnostic thresholds. Indeed, glucose markers have been used as indicators of progression more than other markers.
Glucose levels
The value of glucose as a marker of progression was shown in the Diabetes Prevention Trial-Type 1 (DPT-1). Fasting, 2-h and area under the curve (AUC) glucose levels all gradually increased from over 2 years before diagnosis to approximately 6 months before diagnosis [17] . Since among normoglycemic individuals the risk for T1D is associated with a higher glucose [18] , it appears that glucose levels gradually increase even within the normal range of glycemia. Glucose levels increased markedly between 6 months before diagnosis and diagnosis [19] .
Dysglycemia
Dysglycemia has been utilized as a marker in studies of progression to T1D [20, 21] . In addition, it has been used as an entry criterion [22] [23] [24] in T1D prevention trials, and currently, as a prediagnostic endpoint in a prevention trial. Dysglycemia has various definitions. However, for T1D natural history studies and clinical trials in which 2-h oral glucose tolerance tests (OGTTs) are performed, it is usually defined as one or more of the following: a fasting glucose value from 110-125 mg/dl; a 30, 60, and/or 90-min value of at least 200 mg/dl; a 2-h value from 140-199 mg/dl.
Dysglycemia is a risk factor for T1D among autoantibody positive relatives, although the risk is substantially modified by age [23] . Younger dysglycemic individuals are at much greater risk for T1D than are older individuals with dysglycemia.
Among those followed over a period of years, the vast majority of autoantibody positive relatives pass through a stage of dysglycemia [17] . However, it is not known whether all of those who become dysglycemic, especially older individuals, progress to T1D. Autoantibody relatives with dysglycemia can revert to a normoglycemic state; this is even true for those who ultimately progress to T1D [24] .
There are several considerations in using dysglycemia as a marker for T1D progression. As it covers a wide range of glucose levels, the risk for T1D varies among dysglycemic individuals Moreover, the risk implications of dysglycemia can vary substantially between autoantibody positive populations [25] . Also, as the dysglycemic state is so often a precursor to type 2 diabetes (T2D), and T2D is so much more common than T1D, an appreciable proportion of autoantibody positive adults with dysglycemia could actually develop T2D.
Hemoglobin A1c
HbA1c has been shown to increase during the progression to T1D, and has been assessed as a potential prediagnostic endpoint [26] [27] [28] . A HbA1c value of at least 6.5% (the value currently used as a diagnostic threshold for T1D) was highly specific, but not sensitive for diagnosing T1D in autoantibody positive individuals [27] . Thus, the 6.5% threshold value does not appear useful for diagnosing T1D at an earlier stage of pathogenesis in those individuals. Still, additional studies of HbA1c during progression might provide new insights into the natural history of the disorder.
The 6-month progression scale
The progression to dysglycemia is used as a prediagnostic endpoint in a current prevention trial. However, trials with such prediagnostic endpoints can still be quite prolonged, as they are open-ended. Another approach for shortening trials is to use alternative endpoints indicative of short-term change during progression.
Evidence that glycemia can increase for several years prior to the diagnosis of T1D [17] has been a basis for developing such an alternative endpoint. The PS6 M [29 & ] is a glucose measure that is indicative of the change in glycemia (the sum of 30, 60, 90, and 120-min glucose values from OGTTs) over 6 months relative to the expected change for those not progressing to T1D. The PS6 M was developed from the DPT-1 and Trial Net Pathway to Prevention (PTP) studies. A PS6 M value of 0 corresponds to the value expected for a typical nonprogressor to T1D. Thus, negative values would indicate a smaller degree of progression than the typical nonprogressor, whereas positive values would indicate a greater degree of progression. As PS6 M values increase above 0, 6-month glycemic progression increases. PS6 M values vary according to autoantibody number [29 & ], which suggests that the PS6 M could be used to develop shorter trials with finite (i.e., 6 months) rather than open-ended follow-up.
INSULIN MARKERS
The loss of insulin secretion is a fundamental outcome of T1D pathology, yet there is relatively little longitudinal information about insulin secretion during the progression to T1D. Most of the information is derived from C-peptide analyses (see below).
First-phase insulin response
The first-phase insulin response (FPIR), which is the earliest response to a glucose load during an i.v. glucose tolerance test, can decrease years before the diagnosis of T1D, and is predictive of the disorder [11, [30] [31] [32] [33] [34] [35] . Although few studies have examined changes in the FPIR during progression, a study showed that on average there is a gradual loss of the FPIR until 1-2 years prior to diagnosis, after which the decline accelerates [34] (Fig. 2) .
C-PEPTIDE MARKERS
The AUC C-peptide from OGTTs is predictive of T1D [11, 18] , and both the AUC and peak C-peptide have been followed longitudinally prior to the diagnosis of T1D [17]. These overall measures of C-peptide tend to change little until about 6 months before diagnosis, after which there is an appreciable decline [19] . Figure 3 shows a substantial rate of decline of the peak C-peptide from 6 months prior to diagnosis to within 3 months after diagnosis.
More information regarding insulin loss can be obtained by partitioning OGTTs into earlier and later C-peptide responsiveness [36] . The 30-0 minute C-peptide, which correlates with the FPIR [36] , appears to be a more sensitive indicator than either the AUC or peak C-peptide for examining the decline in C-peptide responsiveness. A decrease in the 30-0 minute C-peptide difference was evident at least 2 years before diagnosis ( Fig. 4 ) in DPT-1. There is a more marked decline 1-2 years prior to diagnosis, which mirrors the decline in the FPIR.
Measures of later C-peptide secretion (after 30 minutes) suggest that there is a compensatory response for the deficient early response during progression. During the last 2 years of progression, the C-peptide response after 30 minutes is actually greater than that in nonprogressors (Fig. 5) , and there is a delay in the timing of the peak C-peptide [36] .
C-peptide measures have not been used as prediagnostic endpoints, although they have been assessed for this purpose [28] . The AUC and peak C-peptide are used as endpoints for trials designed to prevent the loss of insulin secretion after diagnosis [37] [38] [39] [40] [41] .
COMBINED MARKERS
Combinations of markers can provide more prediction accuracy than single markers, although they tend to have less direct pathogenic relevance. As will be evident below, in addition to higher prediction accuracy, combinations of markers can provide a unique approach for developing prediagnostic and diagnostic endpoints.
Diabetes Prevention Trial Type-1 Risk Score
Using proportional hazards regression modeling, the Diabetes Prevention Trial Type-1 Risk Score (DPTRS) was developed from DPT-1 OGTT data to refine the prediction of T1D [35] . The DPTRS combines age, BMI, fasting C-peptide, the sum of glucose values from 30-120 min, and the sum of C-peptide values from 30-120 min. When those variables were included together in a regression model, the associations with T1D were positive for the BMI, fasting C-peptide, and glucose sum, and negative for age and the C-peptide sum. The DPTRS was subsequently validated in the TrialNet Pathway to Prevention Study [42] . A combination of the DPTRS with another risk score, the autoantibody risk score [43] , which predicts T1D according to autoantibody type and titer, has even greater prediction accuracy. When a DPTRS value of 9.00 is exceeded during OGTT surveillance, a diagnosis of T1D becomes a virtual certainty [44] . Thus, that DPTRS threshold could be indicative of a point at which the DPTRS becomes diagnostic of T1D rather than just predictive. This led to the development of another marker, the Index60 (see below), which could potentially be used as a criterion for diagnosis.
Index60
Glucose diagnostic criteria for T1D and T2D have been the same for a number of years, despite differences in the pathogenesis of the disorders. Moreover, current diagnostic criteria for T1D do not take into account the severe insulin deficiency that is present. In contrast with standard glucose criteria, Index60 [45 && ] is a potential diagnostic threshold for T1D that includes both glucose and C-peptide measurements. Derived with proportional hazards modeling, the Index60 combines glucose (60-min glucose) and C-peptide measures (fasting and 60-min C-peptide). It can be calculated from a 1-h OGTT with only two blood samples. Since it was developed to serve as a metabolic diagnostic indicator of T1D, it does not include age and BMI as does the DPTRS. As might be expected, the Index60 correlates with the DPTRS and therefore could also be used for prediction. The Index60 was assessed as a possible endpoint for T1D using both DPT-1 and TrialNet pathway to prevention data. When an Index60 threshold of at least 2.00 was utilized, a virtual diagnosis of T1D could be made before a diagnosis based on standard glucose criteria. In DPT-1, the first OGTT exceeding a threshold of at least 2.00 occurred approximately 1 year before a diagnosis according to standard OGTT glucose criteria. The C-peptide levels declined considerably in the interval from the first OGTT with Index60 at least 2.00 to the time of diagnosis (Fig. 6 ). The data indicated that an Index60 threshold of at least 2.00 could be used alone or together with standard glucose criteria for diagnosis. These findings suggest that the use of an Index60 threshold of at least 2.00 could result in an earlier clinical diagnosis of T1D and shorten prevention trials.
By using a lower threshold (e.g., !1.00 instead of !2.00), the Index60 also has potential as an earlier prediagnostic endpoint. The combination of glucose and C-peptide measurements suggests that Index60 might be a more specific indicator of T1D than dysglycemia, which is also a common precursor for T2D.
OTHER MARKERS
As a marker of b-cell death, unmethylated DNA, has potential utility for studying progression [46 && ]. Repeated measurements of this marker during progression could provide a great deal of information about the timing of the loss of b-cells. It will be of interest to further examine the association between insulin loss and b-cell death to determine the extent to which the decline in insulin secretion is related to the loss of b-cells.
The b-cell sensitivity to glucose is a marker that has already shown value for studying progression. In a DPT-1 study, the b-cell sensitivity to glucose decreased just prior to the accelerated increase in glucose that occurs prior to progression [47] . This finding suggests that future studies of b-cell sensitivity to glucose will provide valuable additional information.
There are several other markers that have potential for improving our understanding of the progression to T1D. New techniques that are being developed to measure islet inflammation and b-cell mass have promise in this regard. Existing and new assays of T-cells and cytokines could also be useful for studying progression. MicroRNAs could provide new information pertinent to genetic control mechanisms during progression. Additional metabolic indices followed serially during progression, such as insulin secretory rates, the insulinogenic index, the disposition index, and specific measures of insulin resistance, might also add insights. Finally, further insight should be gained from examining the relation of markers to each other, such as how the decline in insulin secretion relates to changes in autoantibody characteristics.
DEFINING STAGES OF T1D
George Eisenbarth proposed the first comprehensive staging system for T1D [48] . Although some have proposed modifications, Eisenbarth's original proposal has stood the test of time. However, with the additional information that has been accrued regarding the natural history of T1D, it seems possible to add detail to the staging of T1D, especially among those who are autoantibody positive. A proposed staging system for autoantibody positive individuals is shown below. Information from studies of metabolic markers are used as the basis, as those markers have been studied serially. This information is summarized below:
(1) The FPIR and early C-peptide response can be decreased years before diagnosis. There tends to be an accelerated decline in both 1-2 years prior to diagnosis. Paradoxically, the later insulin response (after 30 min) can increase, possibly in response to higher glucose levels. (2) Glucose levels within the normal range of glycemia are predictive of T1D. (3) Glucose levels can increase years before diagnosis. There tends to be an accelerated increase in glucose 6 months to 1 year prior to diagnosis. (4) Combined markers that include C-peptide and glucose more accurately predict T1D than glucose markers alone. When a high threshold of such markers is exceeded, a clinical diagnosis is virtually inevitable within a few years.
Among those positive for autoantibodies, metabolic progression might be defined by four stages. (1) The time intervals for each stage could vary considerably among individuals. For example, young children might proceed more quickly through each stage. Autoantibody characteristics and other immunologic factors could also modify the rate of progression through the stages. Moreover, it is conceivable that some might proceed to a particular stage, but not to T1D. For example, the presence of a protective factor or the absence of a causative factor could prevent movement from the stage of gradual progression to the stage of accelerated progression. Factors that modify progression deserve extensive exploration. As we learn more about the progression to T1D from new and existing markers, the staging will be further refined.
CONCLUSION
Markers have provided valuable insights into the pathogenesis of T1D. In addition, those markers have practical applications for improving the designs of prevention trials and even potentially for diagnosing T1D at an earlier stage of its development. An earlier diagnosis could result in more effective treatment interventions for preserving insulin secretion. The discovery and development of new markers will almost certainly lead to further progress for delaying or even preventing T1D.
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